Results 251 to 260 of about 356,633 (356)

Current practices of anticoagulant utilization in pediatric patients with acute myeloid leukemia (AML) [PDF]

Abbey Elsbernd, James W. Antoon, Lucas E. Orth   +2 more
openalex   +1 more source

Nigericin‐Triggered Phosphodynamics in Inflammasome Formation and Pyroptosis

PROTEOMICS, EarlyView.
ABSTRACT Innate immune signaling relies heavily on phosphorylation cascades to mount effective immune responses. Although traditional innate immune signaling cascades following TLR4 stimulation have been investigated through a temporally quantitative phosphoproteomic lens, far fewer studies have applied these methods to distinct signaling following the
Vanya Bhushan, Clinton J. Bradfield, Sandhini Saha, Sung Hwan Yoon, Iain D. C. Fraser, Aleksandra Nita‐Lazar   +5 more
wiley   +1 more source

On the mechanism of NPM1 mutations in acute myeloid leukemia. [PDF]

Leukemia
Lieber MR, Hsieh CL.
europepmc   +1 more source

The discovery of crotonoside as a nucleoside analogue demonstrates its potential to inhibit acute myeloid leukemia  activity through multiple pathways [PDF]

Jingyi Wang
openalex   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

The Imbalanced Patterns and Clinical Significance of Cytokines in Acute Myeloid Leukemia Microenvironment. [PDF]

Immun Inflamm Dis
Wang R, Jing K, Zhao H, Zheng G, Cai J.
europepmc   +1 more source

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD [PDF]

Mohamed Elemary, Manuel Espinoza-Gutarra, Camille Sylvestre, Hee‐Je Kim, Ali Bazarbachi, Nour Moukalled, Francesca Biavasco, Jae-Sook Ahn, Hyeoung Joon Kim, Sang Kyun Sohn, Mili Shah, Varun Mehra, Muhanad Alhumaied   +12 more
openalex   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Dual Challenge: Managing Complicated Diphtheria in a Child With Acute Myeloid Leukemia. [PDF]

Cureus
Bhattacharya S, Gaire H, Tulsiyan A, Singh A, Gupta A, Dash S, Nandwani S, Sharma A, Singh DK, Girhotra M, Radhakrishnan N.   +10 more
europepmc   +1 more source

Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia [PDF]

Yu Zhu, Lihong Shou, Jie Jin, East China Leukemia Alliance   +3 more
openalex   +1 more source